Bendamustine-rituximab in mantle cell lymphoma
Mené sur 57 patients âgés de plus de 60 ans (âge médian : 71 ans) et atteints d'un lymphome à cellules du manteau, cet essai de phase II évalue l'efficacité, du point de vue du taux de réponse complète, et la toxicité d'un traitement de première ligne administré par voie intraveineuse combinant rituximab, bendamustine et cytarabine à faible dose
Since bendamustine and rituximab became standard first-line therapy for older patients (aged ≥60 years) with mantle cell lymphoma, there has been a race to build on its success. In The Lancet Haematology, Carlo Visco and colleagues1 present the results of a phase 2 trial of bendamustine–rituximab plus low-dose cytarabine (RBAC500) in patients with mantle cell lymphoma. 52 (91%) of 57 patients achieved a complete response (lower limit of one-sided 95% CI 85%) and 2 year progression-free survival was 81% (95% CI 68–89), results that compare favourably with those of bendamustine–rituximab alone (complete response 30–40%; median progression-free survival roughly 3 years),2,3 establishing RBAC500 as a prime regimen for study in phase 3 trials.
The Lancet Haematology , commentaire, 2015